Italy

Key Insights

1
Italy has no approved psychedelic therapy; patients can access esketamine for treatment-resistant depression, while ketamine is largely limited to off-label or hospital use under physician responsibility.
2
The database shows 3 psychedelic trials in Italy, 2 active, with ketamine, placebo and esketamine as the only studied compounds; ketamine and esketamine dominate the active pipeline.
3
Italy’s standout contribution is the REAL-ESK multicentre network, which has turned esketamine into a national real-world evidence programme spanning multiple psychiatric centres.
4
Momentum is clinical, not regulatory: AIFA’s recent publications and Italian academic groups are pushing ketamine/esketamine protocols, safety pathways and longer-term outcome data.

Medical Only (Private)

Reimbursed Care Access

Italy maintains a largely prohibition‑based approach to classical psychedelics: most classic hallucinogens (psilocybin, MDMA, mescaline, DMT, 5‑MeO‑DMT, 2C‑X, ibogaine, ayahuasca) are controlled under the DPR 309/1990 framework and may only be accessed in authorised clinical research or via tightly regulated medical channels when a licensed medicinal product exists. The one broadly available, reimbursed pharmaceutical in the psychedelic-adjacent space is esketamine (Spravato), which is classified for hospital use with national reimbursement (AIFA Class H); ketamine itself remains a controlled medicine used in hospital/clinical settings and in private off‑label practice for indications like anaesthesia and, in some private clinics, for treatment‑resistant depression but is not reimbursed by the SSN for that psychiatric indication. Citations to primary Italian regulatory acts and official Gazzetta/Ufficiale determinations are included inline below for each compound entry.

Full guide →